局部晚期肠癌患者术后卡培他滨单药维持治疗的临床观察  

Clinical Observation of Capecitabine as Maintenance Treatment after Operation for Local Advanced Colorectal Cancer

作　　者：周文星[1] 张文 宋超 戴发祥 ZHOU Wenxing;ZHANG Wen;SONG Chao(Liuhe Hospital Affiliated to Yangzhou University Medical College,Nanjing,211500)

机构地区：[1]扬州大学医学院附属六合医院

出　　处：《实用癌症杂志》2019年第9期1523-1525,共3页The Practical Journal of Cancer

摘　　要：目的探讨卡培他滨在Ⅲ期结直肠癌辅助化疗后维持治疗的有效性及安全性。方法60例完成术后辅助化疗的Ⅲ期结直肠癌患者随机分为观察组和维持治疗组,每组30例。观察组常规随访观察,维持治疗组予卡培他滨单药维持化疗。观察2组的3年无瘤生存率(DFS)及5年总生存率(OS),维持治疗组的不良反应。结果维持治疗组与观察组相比,3年DFS分别为70.0%和46.7%,5年OS分别为60.0%和36.7%,差异有统计学意义(P<0.05)。维持治疗组的常见不良反应多为Ⅰ~Ⅱ级,对症治疗后可好转。结论Ⅲ期结直肠癌患者辅助化疗后卡培他滨单药维持治疗可改善患者的DFS和OS,且耐受性好,有望成为结直肠癌术后的治疗策略之一。Objective To observe the clinical efficacy and safety of capecitabine as maintenance treatment after operation for local advanced colorectal cancer.Methods 60 patients with stageⅢcolorectal cancer after adjuvant chemotherapy were randomly divided into the control group and the treatment group,30 cases per group.The treatment group was given capecitabine as maintenance treatment,while the control group was observed.The 3-year disease free survival(DFS)and 5-year overall survival(OS)of the 2 groups were observed,and the adverse reactions of the maintenance treatment group were observed.Results 3-year DFS(70.0%)and 5-year OS(60.0%)in the maintenance treatment group were higher than those of the control group(46.7%and 36.7%),and the difference was statistically significant(P<0.05).The common adverse reactions in the maintenance treatment group were mostly levelⅠ~Ⅱ,which could be improved after symptomatic treatment.Conclusion Capecitabine as maintenance treatment after adjuvant chemotherapy for stageⅢcolorectal cancer can improve DFS and OS of patients with good tolerance,which is expected to be one of the treatment strategies after colorectal cancer surgery.

关 键 词：结直肠癌 辅助化疗 卡培他滨 维持治疗 

分 类 号：R735.37[医药卫生—肿瘤] R735.35[医药卫生—临床医学]